Mylan NV Forecasted to Post FY2019 Earnings of $4.20 Per Share (NASDAQ:MYL)

Mylan NV (NASDAQ:MYL) – Equities researchers at Cantor Fitzgerald raised their FY2019 earnings estimates for shares of Mylan in a research report issued to clients and investors on Sunday, November 10th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn $4.20 per share for the year, up from their previous forecast of $4.10. Cantor Fitzgerald also issued estimates for Mylan’s FY2020 earnings at $4.32 EPS.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.03. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.01 billion. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.25 earnings per share.

A number of other analysts have also recently commented on MYL. Evercore ISI restated a “buy” rating on shares of Mylan in a research report on Friday, August 9th. SunTrust Banks upped their price target on Mylan from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Mizuho upped their price target on Mylan from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Cfra cut Mylan from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th. Finally, Wolfe Research assumed coverage on Mylan in a research report on Friday, July 19th. They issued an “outperform” rating and a $27.00 price target for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company’s stock. Mylan has a consensus rating of “Hold” and an average price target of $27.97.

Shares of MYL opened at $17.27 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. The business has a 50-day simple moving average of $18.75 and a two-hundred day simple moving average of $19.56. The stock has a market cap of $9.09 billion, a price-to-earnings ratio of 3.77, a PEG ratio of 0.95 and a beta of 1.75. Mylan has a 52 week low of $16.63 and a 52 week high of $36.09.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC boosted its stake in Mylan by 170.0% during the second quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock valued at $29,000 after buying an additional 957 shares during the last quarter. NuWave Investment Management LLC boosted its stake in Mylan by 1,111.0% during the second quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock valued at $42,000 after buying an additional 2,011 shares during the last quarter. Rational Advisors LLC boosted its stake in Mylan by 1,111.0% during the second quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock valued at $42,000 after buying an additional 2,011 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Mylan by 92.9% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,367 shares of the company’s stock valued at $46,000 after buying an additional 1,140 shares during the last quarter. Finally, CSat Investment Advisory L.P. boosted its stake in Mylan by 258.9% during the second quarter. CSat Investment Advisory L.P. now owns 2,835 shares of the company’s stock valued at $54,000 after buying an additional 2,045 shares during the last quarter. 84.19% of the stock is owned by hedge funds and other institutional investors.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: What is the LIBOR?

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.